- Home
- »
- Pharmaceuticals
- »
-
U.S. Artemisinic Acid Market Size, Industry Report, 2033GVR Report cover
U.S. Artemisinic Acid Market (2025 - 2033) Size, Share & Trends Analysis Report By Product (Antimalarial Injections, Antimalarial Tablets), And Segment Forecasts
U.S. Artemisinic Acid Market Summary
The U.S. artemisinic acid market size was estimated at USD 236.6 million in 2024 and is projected to reach USD 367.7 million by 2033, growing at a CAGR of 5.0% from 2025 to 2033. The primary factors driving the U.S. artemisinic acid market include an increase in malaria cases connected to international travel, the rising global resistance to traditional antimalarials, government-supported stockpiling initiatives, and expanded research and development in semi-synthetic production methods.
Key Market Trends & Insights
- By product, the antimalarial tablets segment held the highest market share of 80.8% in 2024 and is expected to grow at the fastest CAGR over the forecast period.
Market Size & Forecast
- 2024 Market Size: USD 236.6 Million
- 2033 Projected Market Size: USD 367.7 Million
- CAGR (2025-2033): 5.0%
Prism AI by Grand View Research Free to tryAsk a question about the U.S. artemisinic acid marketTry asking✓Every figure cited from GVR research Prefer the report? Download free sample →
The rise of Plasmodium falciparum strains resistant to traditional antimalarial drugs in Africa and Southeast Asia is prompting healthcare providers and policymakers to prioritize access to fast-acting artemisinin-based treatments. As resistance patterns evolve, U.S. institutions increase their reliance on advanced artemisinic formulations, driving imports, R&D investment, and stockpiling of effective therapies to ensure readiness against more virulent malaria forms.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,Download Free Sample Report
Furthermore, biotechnology innovations such as engineered Saccharomyces cerevisiae (yeast)-have enabled more stable and scalable production of artemisinic acid. This reduces reliance on agricultural sources such as Artemisia annua, vulnerable to climate and yield variability. As pharmaceutical companies adopt these methods, the U.S. market benefits from enhanced production reliability and cost-efficiency, supporting broader distribution and emergency preparedness.
Product Insights
Based on product, the antimalarial tablets segment accounted for the largest revenue share of 80.8% and is expected to grow at the fastest CAGR over the forecast period due to rising global travel to malaria-endemic regions. As international travel rebounds post-pandemic, more Americans are visiting malaria-prone countries, increasing the demand for preventive and curative antimalarial medications. During January–December 2023, there were 68 imported malaria cases: San Diego, California (27), Pima, Arizona (18), and El Paso, Texas (23), in comparison to 28 cases in 2022. This increases prescription rates for artemisinin-based combination therapies (ACTs) in travel clinics. Furthermore, rising awareness among travelers and improved diagnostic capabilities have expanded the U.S. artemisinic acid market’s relevance beyond domestic needs.
To learn more about this report,Download Free Sample Report
The antimalarial Injections segment is projected to grow significantly over the forecast period. With increasing global mobility and travel to sub-Saharan Africa, the U.S. reports approximately 2,000 malaria cases annually, the majority caused by P. falciparum and linked to recent travel in Africa. Hospital protocols now emphasize immediate treatment to reduce mortality, driving demand for injectable artesunate.
Key U.S. Artemisinic Acid Company Insights
Some of the key players in the U.S. artemisinic acid market include Sanofi, KPC Pharmaceuticals, Inc., Guilin Pharmaceutical Co., Ltd., and others.
-
Sanofi, a global biopharmaceutical leader operating across pharmaceuticals, vaccines, and consumer health. Sanofi’s semi-synthetic artemisinin supports antimalarial therapies, underscoring its role in healthcare innovation and global disease management.
Key U.S. Artemisinic Acid Companies:
- Sanofi
- KPC Pharmaceuticals, Inc.
- Guilin Pharmaceutical Co., Ltd
- Calyx Chemicals and Pharmaceuticals Ltd.
- Novartis Pharmaceuticals Corporation
- Ipca Laboratories Inc.
- Cipla USA Inc.
- SHINPOONG. Co, Ltd.
U.S. Artemisinic Acid Market Report Scope
Report Attribute
Details
Market size value in 2025
USD 249.7 million
Revenue forecast in 2033
USD 367.7 million
Growth rate
CAGR of 5.0% from 2025 to 2033
Actual data
2024
Historical period
2021 - 2023
Forecast period
2025 - 2033
Quantitative units
Revenue in USD million/billion, and CAGR from 2025 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Product
Key companies profiled
Sanofi; KPC Pharmaceuticals, Inc; Guilin Pharmaceutical Co., Ltd; Calyx Chemicals and Pharmaceuticals Ltd.; Novartis Pharmaceuticals Corporation; Ipca Laboratories Inc.; Cipla USA Inc.;SHINPOONG. Co, Ltd.
Customization scope
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
U.S. Artemisinic Acid Market Report Segmentation
This report forecasts revenue growth at U.S. artemisinic acid market and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. artemisinic acid market report based on product.
-
Product Outlook (Revenue, USD Million, 2021 - 2033)
-
Antimalarial Injections
-
Antimalarial Tablets
-
Frequently Asked Questions About This Report
The U.S. artemisinic acid market was valued at approximately USD 236.6 million in 2024 and is projected to reach USD 249.7 million in 2025.
The U.S. artemisinic acid market is expected to grow at a CAGR of 5.00% from 2025 to 2033, reaching USD 367.7 million by 2033.
Based on product, the antimalarial tablets segment accounted for the largest revenue share of 80.8% and is expected to grow at the fastest CAGR over the forecast period due to rising global travel to malaria-endemic regions.
Key players in the U.S. artemisinic acid market include Sanofi, Guilin Pharmaceutical, KPC Pharmaceuticals, Inc. and Calyx Chemicals and Pharmaceuticals Ltd
Key factors driving the market growth include the increasing prevalence of malaria, which creates a continuous need for effective treatments. Advancements in synthetic biology and fermentation technologies have also played a significant role by enabling cost-effective production of artemisinic acid, making it more accessible.
About the Author(s)
Pharmaceuticals Research Team
Healthcare · PharmaceuticalsThis report was authored by the pharmaceuticals research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the pharmaceuticals segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.